Nonavalent HPV vaccine
Phase 3Vaccine
Nonavalent HPV vaccine is one of 30 biologic programs targeting Immunology. It is currently in Phase 3.
4
Indications
5
Total Trials
5
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Papilloma
#DrugCompanyPhaseTrials
1Vistide
GileadApproved
Celebrex
PPhiladelphia Eye Associates
Approved
HPV Vaccine
SShanghai Zerun Biotechnology Co.,Ltd
Phase 3
Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 3
Gardasil9
Merck & Co.Phase 3
Paraplatin
AAvyxa
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Nonavalent HPV vaccine
XXiamen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vaccination1 trial
Papilloma1 trial
Human Papilloma Virus1 trial
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Active, not recruiting·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT02834637·930 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nonavalent HPV vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 3[1]
- Company
- XXiamen University